Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Gilead | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Gilead

Harvoni drives revenues, up 26% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Gilead

2Q Revenues: $8.2 billion (+26%)

2Q Earnings: $4.5 billion (+23%)

FY Revenues: $15.8 billion (+37%)

FY Earnings: $8.8 billion (+50%)

Comments: Antiviral product sales increased to $7.6 billion in the quarter, up 27% driven by Hep C drug Harvoni(with sales of $3.6 billion in the quarter and $7.2 billion YTD), which was approved in the U.S. and Europe in 4Q14, partially offset by a decrease in sales of Sovaldi (down 63% to $1.3 billion) due primarily to the uptake in Harvoni. Other product sales, which include Letairis(ambrisentan), Ranexa (ranolazine) and AmBisome(amphotericin B liposome for injection), were $495 million in the quarter compared to $401 million  

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters